Brean Murray Raises PT on Inhibitex to $26
Brean Murray Carret & Company has raised the price target on Inhibitex (NASDAQ: INHX) from $19 to $26 after the company announced its plans to have all outstanding shares acquired by Bristol-Myers Squibb (NYSE: BMY) for $26/share. Buy rating is maintained on INHX.







